Shobhna Ladva: Aspen Pharma EME Raises Awareness of Blood Clot Risks During Hormonal Transitions
Shobhna Ladva, Women’s Health Brand Lead of Europe and Middle East at Aspen Pharma EME, Head of Women’s Health Franchise of UK and Ireland at Bayer UK, shared Aspen Pharma EME’s post on LinkedIn:
“As October shines a spotlight on menopause, its a timely reminder that women’s health is about so much more than reproductive organs and fertility.
Women’s health journeys are complex and ever evolving.
Whether its menstrual health, pregnancy, menopause, cardiovascular disease, blood clot risk, cardiovascular health, bone health, mental wellbeing, metabolic health, and many other conditions can significantly impact women, particularly during times of hormonal transition.
Awareness campaigns like World Thrombosis Day play a crucial role in helping women understand risks that are often overlooked, yet can have life-changing consequences.
A truly comprehensive approach to women’s health means looking beyond individual conditions and supporting women through every stage of life.
Because women’s health is whole-body health.”
Aspen Pharma EME shared a post on LinkedIn:
“Blood clots can affect anyone.
Understanding your risk can help you take action.
World Thrombosis Day aims to raise awareness, help people recognize the signs, and support the prevention of thrombosis.
This year’s campaign focuses on raising awareness of how blood clot risk can evolve throughout a woman’s life, from reproductive health to pregnancy, postpartum, menopause, and beyond.
Learn about risk factors.
Know the signs.
For more information, visit World Thrombosis Day.”

Stay updated with Hemostasis Today.
-
Oct 19, 2026, 13:11Giulia Furnari: Connecting With Global Hematology Experts at IACH 2026
-
Oct 19, 2026, 12:46Andrew Choong: Recognizing Thrombosis Before It Becomes Life-Threatening
-
Oct 19, 2026, 11:37Beth Faiman: APSHO Fellows Celebrated for Advancing Hematology and Oncology Practice
-
Oct 19, 2026, 11:26Emanuele Pacini: Myelodysplastic Syndromes Research Featured at JSH Annual Meeting in Kyoto
-
Oct 19, 2026, 10:57Jesmond Dalli: How Erythroblasts Shape Neutrophil Development and Function
-
Oct 19, 2026, 10:41Hisham Fahmi: SCD – Should Gene Editing Begin Before Organ Damage?
-
Oct 19, 2026, 10:33Pallavi Madhiraju: YARTEMLEA Faces Another European Rejection Despite FDA Approval
-
Oct 19, 2026, 10:28Brig Tathagata Chatterjee: Acute Leukemias in AYAs at the Japanese Society of Hematology Conference
-
Oct 19, 2026, 10:27Heather M. Johnson: Join the Discussion on Optimizing the CTEPH Diagnostic Pathway